Takeaway
Spatial patterns of dopamine transporter (DAT) binding, as demonstrated by [18F]fluoro-propyl-carbomethoxy-iodophenyl-tropane ([18F]FP-CIT) positron emission tomography (PET), can reflect specific clinical features of multiple system atrophy (MSA).
Why this matters
It is thought that spatial patterns of neurodegeneration in striatal and extrastriatal regions may reflect various MSA clinical symptoms; however, this has not been clearly elucidated via in vivo studies, with MSA pathophysiology currently confirmed by autopsy.
The demonstration of DAT spatial patterns linked to clinical MSA phenotypes may have implications for targeted therapy development aimed at specific MSA subtypes; however, further study utilizing longitudinal and postmortem designs is required to validate this.